Barinthus Biotherapeutics plc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2020 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Barinthus Biotherapeutics plc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2020 to Q1 2023.
  • Barinthus Biotherapeutics plc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending March 31, 2023 was $172K, a 99% decline year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2023 $172K -$17.8M -99% Mar 31, 2023 10-Q 2023-05-12
Q4 2022 $323K +$303K +1515% Dec 31, 2022 10-Q 2023-11-09
Q3 2022 $26K -$16K -38.1% Sep 30, 2022 10-Q 2022-11-10
Q1 2022 $18M +$17.7M +5673% Mar 31, 2022 10-Q 2022-05-11
Q4 2021 $20K -$498K -96.1% Dec 31, 2021 10-K 2023-03-24
Q3 2021 $42K Sep 30, 2021 10-Q 2021-11-12
Q2 2021 $37K Jun 30, 2021 10-Q 2021-08-12
Q1 2021 $312K Mar 31, 2021 10-Q 2021-06-14
Q4 2020 $518K Dec 31, 2020 10-K 2022-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.